ProCE Banner Activity

CE

Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions

Podcast Episodes
Listen to Sandra E. Kurtin, PhD, ANP-C, AOCN, discuss managing drug–drug and drug–food interactions to minimize adverse events in patients receiving BTK inhibitors.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Released: July 27, 2021

Expiration: July 26, 2022

No longer available for credit.

Share

Faculty

Sandra E. Kurtin

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene Ltd

Janssen administered by Scientific Affairs

Pharmacyclics AbbVie

Target Audience

This educational program is intended for oncology nurses and physician assistants specializing in hematology/oncology involved in the care of patients with B-cell malignancies being treated with a BTK inhibitor.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Avoid adverse reactions to BTK inhibitors by managing drug–drug and drug–food interactions

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed that she has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Epizyme, Incyte, and Pharmacyclics.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Daniel Thibodeau, DHSc, MHP, PA-C

Professor
Physician Assistant Program
Doctor of Medical Science Program
Eastern Virginia Medical School
Physician Assistant
Division of Cardiology
Sentara Medical Group
Sentara Health Systems
Norfolk, Virginia

Daniel Thibodeau, MHP, PA-C, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 26, 2022. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 27, 2021, through July 26, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and oncology nurses to optimally care for patients with B-cell malignancies being treated with a BTK inhibitor.